$ORKA News

Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis - Slideshow

Oruka Therapeutics Files Prospectus For Offering 9.66M Common Shares

Oruka Therapeutics shares are trading lower after the company priced an upsized $700 million public offering of 9.66 million shares at $72.50 per share.

HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $120

UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $100

Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $160

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Oruka Therapeutics Launches $500M Public Offering

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $151

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics shares are trading higher after the company announced interim results from EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.

Oruka Therapeutics Announces Interim Results From EVERLAST-A Phase 2a Trial Of ORKA-001, Half-Life Extended IL-23p19 Monoclonal Antibody, In Moderate-To-Severe Plaque Psoriasis

Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $85

Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $125 Price Target

BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $78